The US FDA has approved Medtronic’s 780G for use with rapid-acting insulin and with Abbott’s type 2 diabetes-specific sensor.

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that ...

Medtronic (NYSE:MDT) today announced three U.S. milestones expanding access to its MiniMed 780G automated insulin delivery system.

Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic began the U.S. rollout on Tuesday of its latest ...

GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...

MiniMed Go™ is the first and only smart MDI system that automatically integrates insulin dosing and glucose data in a single app to provide empowering insights for individuals on multiple daily ...

MiniMed Go is the first and only smart MDI system that automatically integrates insulin dosing and glucose data in a single app to provide empowering insights for individuals on multiple daily ...